
Oligomerix Inc Profile last edited on: 9/20/2022
CAGE: 4PQQ8
UEI: MHB5HVJVAK87
Business Identifier: Target identification and validation technologies: enhancing drug discovery process for neurodegenerative diseases Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 14
County: Bronx
Congr. District: 14
County: Bronx
Public Profile
An emerging biotechnology company, Oligomerix is focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimers disease. With a focus on oral, small molecule, tau self-association inhibitors, Oligomerix seeks to develop therapies for Alzheimers disease and other dementias that are easy to administer and cost effective, and which are expected significantly to add to newly emerging high-cost therapeutic options such as the monoclonal antibody targeted against beta-amyloid that was recently approved by the US FDA. Oligomerix is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
20-24Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2023 | 2 | NIH | $3,679,748 | |
Project Title: GMP Production of a TAU Oligomer Inhibitor to Enable Clinical Development for ADRD | ||||
2023 | 2 | NIH | $2,492,927 | |
Project Title: A 26-week rat toxicity study and efficacy and biomarker studies in Tau-APP Alzheimer's mouse model to support a Phase 1b clinical study | ||||
2022 | 2 | NIH | $7,216,306 | |
Project Title: Tau Oligomer Platform Validation Using Lead Series Candidate in Htau Mice | ||||
2020 | 2 | NIH | $2,499,352 | |
Project Title: Scale-Up and Synthesis of a TAU Oligomer Inhibitor to Initiate IND Enabling Studies for AD and ADRD | ||||
2017 | 1 | NIH | $302,112 | |
Project Title: Development of an Alzheimer's disease specific antibody biomarker for a tau oligomer fragment |
Key People / Management
James G Moe -- CEO and Founder
Eliot Davidowitz -- Founder and Chief Scientific Officer
Bob Foerster -- Chief Financial Officer
Patricia Lopez -- Lab Manager
Jack Pasini -- Chief Commercial Officer and Director
Eliot Davidowitz -- Founder and Chief Scientific Officer
Bob Foerster -- Chief Financial Officer
Patricia Lopez -- Lab Manager
Jack Pasini -- Chief Commercial Officer and Director